AOSD: Young vs. Elderly Onset AOSD is an autoinflammatory condition characterized by fevers, arthritis, & rash. It is considered an orphan disease because of its low prevalence - reported anywhere between 16 to 40 per ten million. https://t.co/gvbPkeq2sH https://t.co/J25U6rWNTy

JAMA: cutaneous hallmarks of dermatomyositis. Printable Patient education overview. https://t.co/S7MaAz6fX2 https://t.co/5ETcQRz8Fd

SGLT2 Inhibitors Reduce Gout Flares and CV Events. A cohort analysis shows that gout patients initiating sodium–glucose cotransporter-2 inhibitors (SGLT2is) had lower serum urate levels and fewer gouty flares requiring ED visits or hospitalizations. https://t.co/laOh4CsZ8Z https://t.co/6oas9AWc8j

Are you up-to-date with the relationship between SpA, its comorbidities, and how it impacts patients? Review this update showcasing a present overview of this topic. Sponsored by Novartis Medical Affairs. https://t.co/zirCeZ0Fgh https://t.co/HIwVNoV94H

Rheumatoid vasculitis (RV) metanalysis: RV decreased from 9.1 (1988-2000) to 3.9 (2001-2010) per million. RV risk increased w/ smoking, disease duration, seropositivity, males, HLA-DRB104, HLA-C3. Common: skin (65–88%), CNS(35–63%), cardiac (33%) https://t.co/gBxd9EIvo2 https://t.co/NFMSkeAq5d

A double-blind, sham-controlled RCT of auricular vagus nerve stimulation (VNS) showed NO meaningful improvement in 101 RA completers. @week 12, ACR20 was 25% for VNS vs 27% for sham (NS). Also NS was change in DAS28-CRP (–0.95 vs –0.66)(p 0.06) https://t.co/n4e564a3gN https://t.co/mnVliEuafK

Plantar Fasciitis study of 180 PF patients shows no clinically meaningful difference between pts treated with patient advice plus heel cup alone (PA) versus PA and lower limb exercise (PAX) versus PAX plus corticosteroid injection (PAXI) https://t.co/X5Q1MlmkzW https://t.co/NtbLQv6b2q

RheumNow Live 2024 is nearly here! Among our 25 speakers, Dr. Weber will cover Cardio-Rheumatology Clinic - Identifying CV Risks. Dr. Guma will cover Nutrition in RA. Dr. El Gabalaway will cover the Prevention of RA, all in a session on Success in RA. https://t.co/5kq9KReEsJ https://t.co/L2GiR8Upqn

Best of 2023: PMR: glad or bad tidings? “Life was turned upside down overnight” – PMR patient. https://t.co/l7jZei5Kfm https://t.co/Ct3qlHd34P

Best of 2023: EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome https://t.co/QQ2IEEMQVy https://t.co/M4NHkasFz6

Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease. https://t.co/UAlpww3fmi https://t.co/NpkTgwDuRl